The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Open accessAbstract
Purpose: Tumor cells from approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2, which represent attractive targets for immunotherapy. Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP–cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B–lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33). Patients and Methods: These genetically modified antigen-presenting cells expanded CTLs that were enriched for specificity against type II latency LMP antigens. When infused into 50 patients with EBV-associated lymphoma, the expanded CTLs did not produce infusional toxicities. Results: Twenty-eight of 29 high-risk or multiple-relapse patients receiving LMP-CTLs as adjuvant therapy remained in remission at a median of 3.1 years after CTL infusion. None subsequently died as a result of lymphoma, but nine succumbed to complications associated with extensive prior chemoradiotherapy, including myocardial infarction and secondary malignancies. Of 21 patients with relapsed or resistant disease at the time of CTL infusion, 13 had clinical responses, including 11 complete responses. T cells specific for LMP as well as nonviral tumor-associated antigens (epitope spreading) could be detected in the peripheral blood within 2 months after CTL infusion, but this evidence for epitope spreading was seen only in patients achieving clinical responses. Conclusion: Autologous T cells directed to the LMP2 or LMP1 and LMP2 antigens can induce durable complete responses without significant toxicity. Their earlier use in the disease course may reduce delayed treatment-related mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Epstein–Barr virus: 40 years on
Young, L. S., & Rickinson, A. B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1452 · Cited by 2,227
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,201
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Self-citationRelease of Infectious Epstein-Barr Virus by Transformed Marmoset Leukocytes
Miller, G., & Lipman, M. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.1.190 · Cited by 941
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 824
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Self-citationMonoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Leen, A. M., Myers, G. D., Sili, U., Huls, M. H., Weiss, H., Leung, K. S., Carrum, G., Krance, R. A., Chang, C.-C., Molldrem, J. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1475 · Cited by 545
Self-citationProgressive differentiation and selection of the fittest in the immune response
Lanzavecchia, A., & Sallusto, F. (2002) · Nature Reviews Immunology · doi:10.1038/nri959 · Cited by 495
Tierney, R. J., Steven, N., Young, L. S., & Rickinson, A. B. (1994) · Journal of Virology · doi:10.1128/jvi.68.11.7374-7385.1994 · Cited by 482
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Doubrovina, E., Oflaz-Sozmen, B., Prockop, S. E., Kernan, N. A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J. F., Heller, G., Barker, J. N., et al. (2012) · Blood · doi:10.1182/blood-2011-08-371971 · Cited by 421
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
Bollard, C. M., Aguilar, L., Straathof, K. C., Gahn, B., Huls, M. H., Rousseau, A., Sixbey, J., Gresik, M. V., Carrum, G., Hudson, M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040890 · Cited by 388
Self-citationIncreased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes
Straathof, K. C. M., Bollard, C. M., Popat, U., Huls, M. H., Lopez, T., Morriss, M. C., Gresik, M. V., Gee, A. P., Russell, H. V., Brenner, M. K., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2975 · Cited by 353
Self-citationKüppers, R., Engert, A., & Hansmann, M.-L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61245 · Cited by 286
Grogg, K. L., Miller, R. F., & Dogan, A. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.051953 · Cited by 281
Bollard, C. M., Gottschalk, S., Leen, A. M., Weiss, H., Straathof, K. C., Carrum, G., Khalil, M., Wu, M.-F., Huls, M. H., Chang, C.-C., et al. (2007) · Blood · doi:10.1182/blood-2007-05-091280 · Cited by 278
Self-citationGottschalk, S., Ng, C. Y. C., Perez, M., Smith, C. A., Sample, C., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2001) · Blood · doi:10.1182/blood.v97.4.835 · Cited by 271
Self-citationIcheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, M. H., Schwinger, W., Nathrath, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8495 · Cited by 268
Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D. K., Wang, H.-J., Elashoff, R. M., McBride, W. H., Mukherji, B., et al. (2003) · PubMed · Cited by 255
Donor T Cells to Treat EBV-Associated Lymphoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311017 · Cited by 250
Wierecky, J., Müller, M. R., Wirths, S., Halder-Oehler, E., Dörfel, D., Schmidt, S. M., Häntschel, M., Brugger, W., Schröder, S., Horger, M. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3905 · Cited by 228
Gottschalk, S., Edwards, O. L., Sili, U., Huls, M. H., Goltsova, T., Davis, A. R., Heslop, H. E., & Rooney, C. M. (2003) · Blood · doi:10.1182/blood-2002-05-1514 · Cited by 186
Self-citationChia, W. K., Wang, W.-W., Teo, M. C. C., Tai, W., Lim, W., Tan, E. H., Leong, S. S., Sun, L., Chen, J. J., Gottschalk, S. M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr341 · Cited by 147
Self-citationMeij, P., Leen, A. M., Rickinson, A. B., Verkoeijen, S., Vervoort, M. B. H. J., Bloemena, E., & Middeldorp, J. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10309 · Cited by 111
Mackinnon, S., Thomson, K. J., Verfuerth, S., Peggs, K. S., & Lowdell, M. W. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.003 · Cited by 98
Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Cruz, C. C., Gerdemann, U., Leen, A. M., Shafer, J. A., Ku, S., Tzou, B., Horton, T. M., Sheehan, A. M., Copeland, A. R. M., Younes, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1873 · Cited by 78
Self-citationPeptide length-based prediction of peptide–MHC class II binding
Chang, S. T., Ghosh, D., Kirschner, D. E., et al. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl479 · Cited by 78
Straathof, K. C. M., Leen, A. M., Buza, E. L., Taylor, G. S., Huls, M. H., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.4137 · Cited by 74
Self-citationTreatment of relapsed Hodgkin’s disease using EBV-specific cytotoxic T cells
Rooney, C. M., Roskrow, M., Suzuki, N., Ng, C. Y., Brenner, M. K., & Heslop, H. (1998) · Annals of Oncology · doi:10.1093/annonc/9.suppl_5.s129 · Cited by 50
Self-citationNew response criteria for lymphomas in clinical trials
Cheson, B. D. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn191 · Cited by 27
Tsuchihashi (2000) · doi:10.1002/1521-4141(200006)30:6
Cited by
Epstein–Barr virus: more than 50 years old and still providing surprises
Young, L. S., Yap, L. F., & Murray, P. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.92 · Cited by 856
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682
The Immunology of Epstein-Barr Virus–Induced Disease
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B., & Hislop, A. D. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112326 · Cited by 602
The Global Landscape of EBV-Associated Tumors
Shannon-Lowe, C., & Rickinson, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00713 · Cited by 459
Metadata
- Authors
- Bollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., Pro, B., Liu, H., Wu, M.-F., Lee, D., Sheehan, A. M., Zu, Y., Gee, A. P., Brenner, M. K., Heslop, H. E., & Rooney, C. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-03-10
- Volume
- 32
- Issue
- 8
- Pages
- 798-808
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120020619
- Cited by
- 503
- References
- 44
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.